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abstract
PurposeAge-standardized incidence rates for esophageal cancer (EC) in East Africa have been reported as
disproportionately highcomparedwith theworldwide incidenceof nineper 100,000population. This study
aimed to characterize ECcases seenatMuhimbili National Hospital andOceanRoadCancer Institute in Dar
es Salaam, Tanzania.
Methods Demographic, clinical, and treatment variables were abstracted from charts of patients who
received care for a diagnosis of EC at one or both institutions between 2011 and 2013. Categorical data
were summarized as frequency counts and percentages. Continuous data were presented as medians and
ranges. To compare men and women, Pearson’s x2 and two-sample t tests were applied.
Results Seven hundred thirty-eight unique cases of EC were identified, of whom 68% were men and the
median age was 60 years (range, 19 to 95 years). Notably, 93 cases (13%) were £ 40 years old at
diagnosis. Squamous cell carcinoma was the dominant histology, comprising 90% of cases with
documented histopathology. However, 34% of cases with a diagnosis of EC were not pathologically
confirmed. The stage was documented as locoregional in 4% of cases, locally advanced in 20% of cases,
metastatic in 14% of cases, and unknown in 63% of cases. Of 430 patients who received treatment at
Ocean Road Cancer Institute, 76%were treated with radiation, 44%were treated with chemotherapy, 3%
underwent a cancer-related surgical procedure, and 10% of cases received no cancer-directed therapy.
The median overall survival for all patients was 6.9 months (95% CI, 5.0 to 12.8), regardless of stage at
presentation.
Conclusion Between 2011 and 2013, cases of EC represented a large clinical burden at both institutions.
J Glob Oncol 00. © 2017 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Although the reported worldwide age-standardized
incidence rate for esophageal cancer (EC) is nine
cases per 100,000 population per year,1 this sta-
tistic does not reflect remarkable geographic vari-
ations in incidencerates.Currently,.80%ofcases
and deaths from EC occur within developing coun-
tries. One of the most striking features of EC is the
presence of defined high-incidence geographic
regions, including locales in northern China, north-
eastern Iran, eastern South America, and South
Africa.2,3 Eastern Africa was recently described as
another high-incidence geographic area for EC,4
with incidence and mortality rates significantly
higher than in western,middle, or northern Africa.5
Cancer is not a reportable disease in Tanzania,
with limited data available on burden. In an era in
which increasing attention and resources are be-
ing directed toward noncommunicable diseases
in low- andmiddle-income countries, data regard-
ing the burden of EC to the health care system are
needed to begin building the capacity to provide
care for this deadly disease. With a population of
approximately 4.4 million persons, Dar es Salaam
is the most highly and densely populated urban
area in Tanzania and has the highest average
population growth rate since 2002 (5.6%).5 To
better understand theclinical characteristics of EC
in Tanzania and the associated care burden, this
study aimed to characterize the EC cases seen at
two major referral hospitals in Dar es Salaam,
Tanzania.
METHODS
Study Design
We conducted a retrospective chart review of all
patients diagnosed with EC at Muhimbili National
Hospital (MNH) and Ocean Road Cancer Institute
(ORCI) in Dar es Salaam Tanzania between 2011
and2013.WithinDar esSalaam,MNH is thepublic
teaching hospital affiliated with Muhimbili Univer-
sity of Health and Allied Sciences and is a national
referral hospital with 1,500 beds, admitting 1,000
to 1,200 inpatients per day and providing care to
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. 1,000 outpatients per week.6 Cancer cases
warranting chemotherapy or radiation therapy are
typically referred, following diagnosis, to ORCI,
which is the only specialized facility for cancer
treatment where radiation therapy is available in
Tanzania.
Study Population
All patients > 18 years old who received care at
eitherMNHorORCI between 2011 and 2013 for a
diagnosis of EC were included in this analysis.
Cases of EC were identified at MNH using its
computerized database. Cases of EC at ORCIwere
identified by reviews of the admission registry,
chemotherapy logbook, and radiation therapy log-
book. Because not all patients with a suspected
diagnosis of EC undergo diagnostic biopsies for
pathologic confirmation of malignancy as a result
of the associated out-of-pocket costs, expanded
criteria for inclusion were necessary. Cases were
included on the basis of a histologically confirmed
diagnosis of EC or a clinical diagnosis on the basis
of barium swallow or an esophagogastroduodeno-
scopy without confirmatory biopsy.
Data Collection
This retrospective chart review was approved by
institutional review boards at University of California,
San Francisco and Muhimbili University of Health
and Allied Sciences. Available paper medical re-
cords for all patients with a documented diagnosis
of EC were retrieved, and each was reviewed to
confirm a documented diagnosis of EC. Cases
without a clinical or pathologically documented di-
agnosis of EC were excluded. Names, ages, and
medical record numbers of cases abstracted at
MNH and ORCI were cross-checked to avoid
double-counting patients who received care at both
institutions. Each case was de-identified with a
unique study identification number. Data were en-
tered into Research Electronic Data Capture, a se-
cure Web-based application for data storage.
Demographic, clinical, and treatment variables were
abstracted from the medical records. Demographic
variables included age at diagnosis, sex, ethnicity,
and location of primary residence. Distance traveled
from primary residence to Dar es Salaamwas calcu-
lated by inputting the district of origin into Distance
Calculator.7 Zones of Tanzania were delineated
according to categories used by the 2010 Tanzania
Demographic and Health Survey. Primary referral
hospitals were categorized as private, regional, or
district.
Clinical variables included symptoms at pre-
sentation, anatomic location of primary tumor,
histologic subtype, and disease stage. Date of
diagnosis was recorded as date of the first confir-
matory test result. If dates for diagnostic tests were
not found, the date of first presentation for care
related to the EC diagnosis was used. In cases in
which the anatomic location of the tumor in the
proximal, middle, or distal esophagus was not
documented, the documented distance from in-
cisors was converted to anatomic location: tumors
with a proximal border at, 18 cm were classified
in the upper esophagus; 18 to , 32 cm were
classified in the middle esophagus; and< 32 cm
were classified in the lower esophagus. For those
cases who received treatment for the diagnosis of
EC, details on surgical procedures, administration
of radiation and/or chemotherapy, or receipt of
palliative care were abstracted.
Statistical Methods
Demographic data and clinical characteristics
were summarized with descriptive statistics. Cat-
egorical data were summarized as frequency
counts and percentages, and continuous data
were presented as medians and ranges. To com-
pare betweenmen andwomen, Pearson’s x2 and
two-sample t tests were applied for categorical
data and continuous data, respectively. Overall
survival (OS) was assessed by the Kaplan-Meier
method, and the comparisons of OS among the
different groups of subjects were done by log-
rank test. Statistical significance was declared
at P , .05. All analyses were performed using
the statistical computing software R (http://www.
r-project.org).
RESULTS
Demographic Characteristics
From hospital records at MNH and ORCI, 738
unique cases of EC from Tanzania were identified
as having received care at one or both institutions
between 2011 and 2013. Nearly all cases were
documented as African (n = 686; 93%), and 68%
(n = 468) of cases were men. The overall median
age at diagnosis was 60 years (range, 19 to 95
years). Notably, 93 cases (13%) were< 40 years
old at diagnosis.
Demographic characteristics of all EC cases,
according to institution, are summarized in
Table 1. More than half of all cases (n = 427,
59%) reported having a primary residence in the
Coastal Zone of Tanzania. The median distance
traveled from primary residence to MNH was
194km(range,3 to1,416km)and455km(range,
4 to 1,416 km) from primary residence to ORCI.
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Table 1. Demographic Characteristics of Patients With Esophageal Cancer in Dar es Salaam, Tanzania
Characteristic
Seen Only at ORCI Seen Only at MNH Total Unique Cases
Men Women Total Men Women Total Men Women Total
No. of patients 96 48 144 204 100 304 504 234 738
Age in years (range) 61 (29-95) 58 (21-92) 60 (21-95) 63 (19-93) 58 (29-92) 61 (19-93) 61 (19-95) 58 (21-92) 60 (19-95)
Race/ethnicity, No. (%)
African 87 (91) 44 (92) 131 (91) 204 (100) 100 (100) 304 (100) 468 (93) 218 (93) 686 (93)
Arab 1 (1) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 1 (0) 0 (0) 1 (0)
Unknown 8 (8) 4 (8) 12 (8) 0 (0) 0 (0) 0 (0) 35 (7) 16 (7) 51 (7)
Zone of origin, No. (%)
Central 4 (4) 3 (6) 7 (5) 16 (8) 4 (4) 20 (7) 42 (8) 11 (5) 53 (7)
Coastal 36 (38) 17 (35) 53 (37) 138 (68) 69 (69) 207 (68) 288 (57) 139 (59) 427 (58)
Lake 5 (5) 4 (8) 9 (6) 4 (2) 2 (2) 6 (2) 23 (5) 7 (3) 30 (4)
Northern 38 (40) 13 (27) 51 (35) 21 (10) 16 (16) 37 (12) 89 (18) 44 (19) 133 (18)
Southern Highlands 12 (13) 7 (15) 19 (13) 18 (9) 6 (6) 24 (8) 48 (10) 26 (11) 74 (10)
Zanzibar 1 (1) 3 (6) 4 (3) 4 (2) 1 (1) 5 (2) 9 (2) 4 (2) 13 (2)
Missing 0 (0) 1 (2) 1 (1) 3 (1) 2 (2) 5 (2) 5 (1) 3 (1) 8 (1)
Occupation, No. (%)
Accommodation and
food service
0 (0) 1 (2) 1 (1) 1 (0) 1 (1) 2 (1) 3 (1) 5 (2) 8 (1)
Administration 6 (6) 1 (2) 7 (5) 2 (1) 1 (1) 3 (1) 14 (3) 4 (2) 18 (2)
Agriculture, forestry,
and fishing
12 (13) 2 (4) 14 (10) 11 (5) 2 (2) 13 (4) 63 (13) 27 (12) 90 (12)
Business 10 (10) 3 (6) 13 (9) 9 (4) 1 (1) 10 (3) 47 (9) 11 (5) 58 (8)
Construction and
manufacturing
0 (0) 1 (2) 1 (1) 8 (4) 1 (1) 9 (3) 22 (4) 4 (2) 26 (4)
Human health and
social work
8 (8) 3 (6) 11 (8) 4 (2) 1 (1) 5 (2) 29 (6) 5 (2) 34 (5)
Peasant/no job 20 (21) 11 (23) 31 (22) 50 (25) 22 (22) 72 (24) 125 (25) 68 (29) 193 (26)
Student/military 2 (2) 0 (0) 2 (1) 2 (1) 0 (0) 2 (1) 5 (1) 0 (0) 5 (1)
Other or unknown 38 (40) 26 (54) 64 (44) 117 (57) 71 (71) 188 (62) 196 (39) 110 (47) 306 (41)
Alcohol use, No. (%)
Current use 12 (13) 0 (0) 12 (8) 33 (16) 4 (4) 37 (12) 68 (13) 6 (3) 74 (10)
History of use 36 (38) 10 (21) 46 (32) 74 (36) 8 (8) 82 (27) 218 (43) 43 (18) 261 (35)
Never user 28 (29) 24 (50) 52 (36) 46 (23) 55 (55) 101 (33) 131 (26) 130 (56) 261 (35)
Unknown 20 (21) 14 (29) 34 (24) 51 (25) 33 (33) 84 (28) 87 (17) 55 (24) 142 (19)
Smoking history, No. (%)
Current use 6 (6) 1 (2) 7 (5) 35 (17) 1 (1) 36 (12) 74 (15) 4 (2) 78 (11)
History of use 46 (48) 6 (13) 52 (36) 84 (41) 9 (9) 93 (31) 235 (47) 26 (11) 261 (35)
Never user 31 (32) 27 (56) 58 (40) 37 (18) 54 (54) 91 (30) 124 (25) 147 (63) 271 (37)
Unknown 13 (14) 14 (29) 27 (19) 48 (24) 36 (36) 84 (28) 71 (14) 57 (24) 128 (17)
HIV status, No. (%)
Negative 3 (3) 2 (4) 5 (3) 9 (4) 7 (7) 16 (5) 38 (8) 21 (9) 59 (8)
Positive 1 (1) 2 (4) 3 (2) 0 (0) 6 (6) 6 (2) 5 (1) 11 (5) 16 (2)
Unknown 92 (96) 44 (92) 136 (94) 195 (96) 87 (87) 282 (93) 461 (91) 202 (86) 663 (90)
Abbreviations: MNH, Muhimbili National Hospital; ORCI, Ocean Road Cancer Institute.
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Among individuals for whom smoking status was
documented (433 men and 177 women), 29%
(n = 124) of men versus 83% (n = 177) of women
were documented as never smokers (P , .001).
Among individuals for whomalcohol consumption
history was documented (417 men and 179
women), 31% (n = 131) of men versus 73%
(n = 130) of women were documented as having
no previous or current alcohol consumption
(P , .001). Reporting of patient occupation was
identified in 59% (n = 432) of medical records.
Among all EC cases, 26% (n = 193) of EC cases
were documented as being small-scale subsis-
tence farmers or unemployed (eg, peasants), and
an additional 12% (n = 90) were documented
as working in agriculture, forestry, or fishing
industries.
HIV serostatus was documented for only 10%
(n = 75) of all cases. Only 2% (n = 16) of all EC
cases were documented as HIV positive. Among
patients with documented HIV status, 21% (16 of
75) were HIV positive.
Clinical Characteristics
Of 594 cases seen first at MNH, 266 (45%) were
referred from regional hospitals, 205 (35%) from
district hospitals, and 53 (9%) from private hos-
pitals. For 144 cases referred directly to ORCI for
treatment without being seen at MNH, 56 (39%)
were referred from private hospitals and 44
(30.6%) from regional hospitals.
Table 2 summarizes the clinical characteristics of
EC cases. Squamous cell carcinoma (SCC) was
the dominant histology, comprising 90% of cases
with documented histopathology. However, 34%
of cases with a documented diagnosis of EC were
on the basis of clinical information only and were
not pathologically confirmed. Diagnosis of EC was
made by endoscopy with biopsy for 79%and88%
of cases presenting to MNH and ORCI, respec-
tively. Anatomic location of the tumor was docu-
mented in theproximal ormiddle esophagus in the
majority of cases. Dysphagia to solids was docu-
mented in 100% of cases.
Abdominal ultrasound was the most common
imaging modality used for staging and was per-
formed in 51%of cases at ORCI and 23%of cases
who presented to MNH. The majority of cases
(67%) underwent no staging imaging. Cross-
sectional imaging (eg, computed tomography
scans) was performed only in 1% of all cases.
Stage was documented as locoregional in 4% of
cases, locally advanced in 20% of cases, meta-
static in 14% of cases, and unknown or missing in
63% of cases. Of all cases with documented stage
seen at ORCI, 37%were documented as localized
or locoregional disease versus 20% at MNH.
Treatment Characteristics
Among the 430 cases who received treatment for
their diagnosis of EC at ORCI, intent of treatment
was documented as curative in 46% (n = 196) of
cases, palliative in 46% (n = 199) of cases, and
undocumented in 8% (n = 35) of cases. Of all
cases at ORCI, 76% were treated with radiation
therapy (n = 326), and 44% of cases received
chemotherapy (n = 190), with either palliative or
curative intent. Forty-two percent of patients
(n = 181) received both chemotherapy and radia-
tion as part of their treatment. Ten percent of cases
(n = 39) received no cancer-directed therapy and
were treated with palliative care only. Only 3% of
patients (n = 13) underwent a cancer-related sur-
gical procedure. Of the 430 cases treated at ORCI,
214 (50%) did not complete the initially recom-
mended treatment. Reasons for discontinuation of
treatment are summarized in Figure 1.
Overall Survival
Themedian follow-upwas 1.3months (range, 0 to
35.8months) across all sites; however, duration of
follow-up differed according to site (0.5 months at
MNH v 3.3 months at ORCI v 2.8 months for
patients receiving care at both institutions). Of
the 304 cases who presented to MNH and did
not receive treatment at ORCI, 40%were reported
as dead at date of last contact. Of the 434 cases
who received care at ORCI, 30%were reported as
dead at date of last contact. Kaplan-Meier curves
for OS are shown in Figure 2. ThemedianOS for all
patients was 6.9 months (95% CI, 5.0 to 12.8),
regardless of stage at presentation. The median
OS for cases who received care only at MNH was
1.1months (95%CI, 1.0 to 1.2) versus 10months
(95% CI, 7.2 to 22.4) for cases who presented to
both institutions (P, .001). ThemedianOS could
not be calculated for those who presented only to
ORCI because 50% of patients did not reach the
primary end point during follow-up.
DISCUSSION
Among the738patientswithECwho receivedcare
at two major referral hospitals in Dar es Salaam,
Tanzania between 2011 and 2013, 68% were
men, and nearly all were of African descent. Of
those with histologic confirmation, SCC was the
dominant histology. Our findings regarding the
characteristics of patients with EC in Tanzania
are consistent with previous reports from this
4 jgo.org JGO – Journal of Global Oncology
Ta
bl
e
2.
R
ef
er
ra
la
nd
D
ia
gn
os
tic
P
at
te
rn
s
fo
r
C
as
es
of
Es
op
ha
ge
al
C
an
ce
r
W
ho
P
re
se
nt
ed
to
O
ce
an
R
oa
d
C
an
ce
r
In
st
itu
te
or
M
uh
im
bi
li
N
at
io
na
lH
os
pi
ta
l
Va
ria
bl
e
P
re
se
nt
ed
to
O
R
C
I
P
re
se
nt
ed
to
M
N
H
To
ta
lU
ni
qu
e
C
as
es
M
en
W
om
en
To
ta
l
M
en
W
om
en
To
ta
l
M
en
W
om
en
To
ta
l
P
*
N
o.
of
pa
tie
nt
s
10
1
49
15
0
40
3
18
5
58
8
50
4
23
4
73
8
Ye
ar
of
pr
es
en
ta
tio
n,
N
o.
(%
)
.0
13
20
11
35
(3
5)
16
(3
3)
51
(3
4)
98
(2
4)
65
(3
5)
16
3
(2
8)
13
3
(2
6)
81
(3
5)
21
4
(2
9)
20
12
41
(4
1)
20
(4
1)
61
(4
1)
14
1
(3
5)
59
(3
2)
20
0
(3
4)
18
2
(3
6)
79
(3
4)
26
1
(3
5)
20
13
25
(2
5)
13
(2
7)
38
(2
5)
16
4
(4
1)
61
(3
3)
22
5
(3
8)
18
9
(3
8)
74
(3
2)
26
3
(3
6)
M
ed
ia
n
di
st
an
ce
tr
av
el
ed
in
km
(r
an
ge
)
46
0
(4
-1
,2
94
)
36
3
(1
0-
1,
41
6)
45
5
(4
-1
,4
16
)
19
4
(3
-1
,4
16
)
19
4
(4
-1
,4
16
)
19
4
(3
-1
,4
16
)
19
4
(3
-1
,4
16
)
19
4
(4
-1
,4
16
)
19
4
(3
-1
,4
16
)
,
.0
01
Si
te
of
or
ig
in
al
ca
re
,N
o.
(%
)
,
.0
01
D
is
tr
ic
t
3
(3
)
2
(4
)
5
(3
)
13
0
(3
2)
75
(4
1)
20
5
(3
5)
13
3
(2
6)
77
(3
3)
21
0
(2
8)
P
riv
at
e
38
(3
8)
20
(4
1)
58
(3
9)
32
(8
)
19
(1
0)
51
(9
)
70
(1
4)
39
(1
7)
10
9
(1
5)
R
eg
io
na
l
32
(3
2)
14
(2
9)
46
(3
1)
19
8
(4
9)
66
(3
6)
26
4
(4
5)
23
0
(4
6)
80
(3
4)
31
0
(4
2)
N
o
re
fe
rr
al
ho
sp
ita
l
28
(2
8)
13
(2
7)
41
(2
7)
43
(1
1)
25
(1
4)
68
(1
2)
71
(1
4)
38
(1
6)
10
9
(1
5)
B
as
is
of
di
ag
no
si
s,
N
o.
(%
)
.0
01
EG
D
w
ith
bi
op
sy
89
(8
8)
43
(8
8)
13
2
(8
8)
32
5
(8
1)
13
7
(7
4)
46
2
(7
9)
41
4
(8
2)
18
0
(7
7)
59
4
(8
0)
EG
D
w
ith
ou
tb
io
ps
y
1
(1
)
1
(2
)
2
(1
)
4
(1
)
3
(2
)
7
(1
)
5
(1
)
4
(2
)
9
(1
)
B
ar
iu
m
sw
al
lo
w
4
(4
)
1
(2
)
5
(3
)
43
(1
1)
32
(1
7)
75
(1
3)
47
(9
)
33
(1
4)
80
(1
1)
M
is
si
ng
7
(7
)
4
(8
)
11
(7
)
31
(8
)
13
(7
)
44
(7
)
38
(8
)
17
(7
)
55
(7
)
H
is
to
lo
gy
,N
o.
(%
)
,
.0
01
A
de
no
ca
rc
in
om
a
5
(5
)
2
(4
)
7
(5
)
28
(7
)
6
(3
)
34
(6
)
33
(7
)
8
(3
)
41
(6
)
Sq
ua
m
ou
s
ce
ll
ca
rc
in
om
a
76
(7
5)
37
(7
6)
11
3
(7
5)
22
8
(5
7)
10
3
(5
6)
33
1
(5
6)
30
4
(6
0)
14
0
(6
0)
44
4
(6
0)
C
ar
ci
no
m
a,
N
O
S
0
(0
)
0
(0
)
0
(0
)
2
(0
)
2
(1
)
4
(1
)
2
(0
)
2
(1
)
4
(1
)
C
lin
ic
al
di
ag
no
si
s
on
ly
20
(2
0)
10
(2
0)
30
(2
0)
14
5
(3
6)
74
(4
0)
21
9
(3
7)
16
5
(3
3)
84
(3
6)
24
9
(3
4)
A
na
to
m
ic
tu
m
or
lo
ca
tio
n,
N
o.
(%
)
.0
9
P
ro
xi
m
al
6
(6
)
2
(4
)
8
(5
)
37
(9
)
21
(1
1)
58
(1
0)
43
(9
)
23
(1
0)
66
(9
)
M
id
dl
e
33
(3
3)
19
(3
9)
52
(3
5)
15
6
(3
9)
81
(4
4)
23
7
(4
0)
18
9
(3
8)
10
0
(4
3)
28
9
(3
9)
D
is
ta
l
27
(2
7)
19
(3
9)
46
(3
1)
12
0
(3
0)
29
(1
6)
14
9
(2
5)
14
7
(2
9)
48
(2
1)
19
5
(2
6)
M
is
si
ng
35
(3
5)
9
(1
8)
44
(2
9)
90
(2
2)
54
(2
9)
14
4
(2
4)
12
5
(2
5)
63
(2
7)
18
8
(2
5)
(C
on
tin
ue
d
on
fo
llo
w
in
g
pa
ge
)
5 jgo.org JGO – Journal of Global Oncology
Ta
bl
e
2.
R
ef
er
ra
la
nd
D
ia
gn
os
tic
P
at
te
rn
s
fo
r
C
as
es
of
Es
op
ha
ge
al
C
an
ce
r
W
ho
P
re
se
nt
ed
to
O
ce
an
R
oa
d
C
an
ce
r
In
st
itu
te
or
M
uh
im
bi
li
N
at
io
na
lH
os
pi
ta
l(
C
on
tin
ue
d)
Va
ria
bl
e
P
re
se
nt
ed
to
O
R
C
I
P
re
se
nt
ed
to
M
N
H
To
ta
lU
ni
qu
e
C
as
es
M
en
W
om
en
To
ta
l
M
en
W
om
en
To
ta
l
M
en
W
om
en
To
ta
l
P
*
Im
ag
in
g
m
od
al
iti
es
us
ed
,
N
o.
(%
)
,
.0
01
A
bd
om
in
al
ul
tr
as
ou
nd
50
(5
0)
26
(5
3)
76
(5
1)
94
(2
3)
39
(2
1)
13
3
(2
3)
14
4
(2
9)
65
(2
8)
20
9
(2
8)
X-
ra
y
7
(7
)
1
(2
)
8
(5
)
16
(4
)
4
(2
)
20
(3
)
23
(5
)
5
(2
)
28
(4
)
C
om
pu
te
d
to
m
og
ra
ph
y
sc
an
1
(1
)
1
(2
)
2
(1
)
4
(1
)
0
(0
)
4
(1
)
5
(1
)
1
(0
)
6
(1
)
N
on
e
43
(4
3)
21
(4
3)
64
(4
3)
28
9
(7
2)
14
2
(7
7)
43
1
(7
3)
33
2
(6
6)
16
3
(7
0)
49
5
(6
7)
D
oc
um
en
te
d
st
ag
e
at
di
ag
no
si
s,
N
o.
(%
)
.2
22
Lo
co
re
gi
on
al
4
(4
)
5
(1
0)
9
(6
)
14
(3
)
7
(4
)
21
(4
)
18
(4
)
12
(5
)
30
(4
)
Lo
ca
lly
ad
va
nc
ed
29
(2
9)
18
(3
7)
47
(3
1)
67
(1
7)
30
(1
6)
97
(1
6)
96
(1
9)
48
(2
1)
14
4
(2
0)
M
et
as
ta
tic
17
(1
7)
6
(1
2)
23
(1
5)
49
(1
2)
30
(1
6)
79
(1
3)
66
(1
3)
36
(1
5)
10
2
(1
4)
M
is
si
ng
51
(5
0)
20
(4
1)
71
(4
7)
27
3
(6
8)
11
8
(6
4)
39
1
(6
6)
32
4
(6
4)
13
8
(5
9)
46
2
(6
3)
A
bb
re
vi
at
io
ns
:E
G
D
,e
so
ph
ag
og
as
tr
od
uo
de
no
sc
op
y;
M
N
H
,M
uh
im
bi
li
N
at
io
na
lH
os
pi
ta
l;
N
O
S,
no
to
th
er
w
is
e
sp
ec
ifi
ed
;O
R
C
I,
O
ce
an
R
oa
d
C
an
ce
r
In
st
itu
te
.
*P
va
lu
e
ca
lc
ul
at
io
n
re
fle
ct
s
co
m
pa
ris
on
be
tw
ee
n
pa
tie
nt
gr
ou
ps
th
at
pr
es
en
te
d
to
O
R
C
Iv
er
su
s
M
N
H
.
6 jgo.org JGO – Journal of Global Oncology
region.8 Presentation with advanced symptoms
was common, comparable to reports from other
parts ofEasternAfrica.9This isprobably inpart asa
result of barriers to cancer treatment that exist in
Tanzania, including prohibitive costs of diagnostic
tests and challenges in accessing care.
Althoughwe cannot infer causal associations from
these data, it is notable that documented rates of
current or previous alcohol consumption, smok-
ing, and HIV infection among EC cases are higher
than in the Tanzania population at large.10,11
Although HIV status was documented for only a
small proportion of patients, 21% of those with
documented HIV testing were reported as HIV
positive. This is substantially higher than the over-
all approximately 5% seroprevalence of HIV in
Tanzania among adults ages 15 to 49 years and
merits further evaluation, particularly in light of
recent data from a case-control study in Zambia
that reportedHIV infection as a risk factor for EC.12
Additionally, the Coastal and Northern zones of
Tanzania lead in referrals to both institutions.
These regions are in closest proximity to Dar es
Salaam; thus, referral bias probably accounts for
this finding. The Kilimanjaro region (within the
Northern Zone) of Tanzania is, however, an area
of active investigation as a high-incidence area
within Tanzania.13,14 Further inquiry into the role
of tobacco and alcohol exposures, HIV infection,
as well as unique geographic exposures as pos-
sible contributors to the high incidence of EC in
Tanzania is warranted.
One of the most striking findings is the proportion
of unusually young cases, with 13%of cases< 40
years old at the time of diagnosis. Among the
patients < 40 years old, 56% were men, and
95% of cases with a histopathologic diagnosis
were SCC. Although many patients were < 40
years old, a younger population age structure in
African countries may significantly contribute to a
younger age at cancer diagnosis, compared with
other settings. However, the unusually high rep-
resentation of young individuals could also point
to apossible contribution fromgenetic factors and/
or environmental exposures to the high incidence
of this disease. No significant demographic differ-
ences among the patients < 40 years old at di-
agnosis were identified, when compared with
those older than 40 years.
A significant difference in OS was identified be-
tween cases who received care only at MNH
versus those who received care at ORCI. This
difference in outcomes between patients who
established care at ORCI is probably in part as
the result of patient selection. Notably, 37% of
patientswhopresented toORCIweredocumented
as having locoregional or locally advanced dis-
ease, versus20%of thosewhopresented toMNH,
suggesting that patients with metastatic disease
are less likely to be referred toORCI.Moreover, the
sickest patients probably died atMNHshortly after
presentation and before referral. Although we
acknowledge the limitations of this comparison
as a result of lack of detailed information regarding
prognostic factors, including stage and perfor-
mance status, and nonstandardization of staging
procedures and treatment decisions across pro-
viders, differences in survival suggest that patients
referred to ORCI for consideration for treatment
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reasons for early
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are appropriately selected in this resource-
constrained setting. Given that death is a major
reason for loss to follow-up in Africa, we acknowl-
edge that OS may be overestimated for patients
for whom vital status was unknown at the time of
censoring.
Among patients who received cancer-directed treat-
ments at ORCI, a vast majority were treated with
radiation, either with or without concurrent chemo-
therapy. Intent of treatment was documented by
providers as curative in half of cases, often despite
unknown stage; this perhaps reflects provider opti-
mismin theabsenceofstagingcapabilities.Whereas
systemic chemotherapy would be the mainstay of
clinical care foradvancedEC inadevelopedcountry,
low use of chemotherapy in this cohort may reflect
accessibility of radiotherapy compared with chemo-
therapydrugs. Similarly, self-expandingmetal stents
have been demonstrated as feasible and effective in
palliating inoperable EC in other African settings.15
Currently, stents are not widely available in Tanzania
for palliation of this disease, as the result of pro-
hibitively high commercial pricing and import tax
rates, which are further compounded by the socio-
economic status of patients.
Despite patient selection for referral to ORCI, nearly
half of patients treated at ORCI did not complete
recommended therapies. The high frequency of
treatment cessation as the result of deterioration of
the patient’s clinical status suggests that, despite
careful selection,manypatientswere in factnotwell
enough to tolerate available treatments or that
additional supportive-care resources are needed
to safely perform these treatments. Moreover, this
finding highlights the need to evaluate the role for
radiation therapy in the management of EC, par-
ticularly inpatientswith advanceddisease.We infer
from these data that radiation therapy is used in the
majority of cases, even those with advanced or
metastatic disease, as palliation for obstruction.
However, successful administration of this type of
therapy typically requires a multidisciplinary sup-
port team, including nursing, nutrition, and social
work services. Further inquiry into whether this is
the safest and most efficacious approach in a
resource-constrained setting, in which appropriate
supportive care may not be readily available, is
planned. Specifically, the feasibility and cost-
effectiveness of palliative stenting as an alternative
to radiation to relieve obstruction merits further
inquiry in this and similar settings.
Several limitations of this study must be acknowl-
edged. Because of the retrospective nature, data on
multiple variables of interest were limited by the
absence of documentation in the medical records;
therefore, our findings were potentially subject to
reporting bias. Specifically, 34% of patients did not
have any documented pathologic diagnosis in the
medical record. Amajority of clinical diagnoseswere
accompanied by results from a barium swallow as a
surrogate for histopathologic confirmation; however,
the possibility that noncancer cases were errone-
ously included exists. Similarly, disease stage was
not documented for 63% of cases, reflecting that
cross-sectional imaging is not readily accessible or
routinely used as part of clinical evaluation for EC.
Withonly1%ofECcasesundergoingcross-sectional
imaging, we did not conduct analyses stratified by
stage because of the high likelihood of inaccuracies.
Data abstraction at both institutions was limited to
only medical records that were retrievable, and
cases for which a chart was not located were
omitted. A reported number of 573 and 581 cases
of EC were seen at ORCI in 2012 and 2013,
respectively (unpublished data); thus, it is proba-
ble that available charts underrepresent all cases
of EC. Additionally, follow-up data for many pa-
tients were incomplete, highlighting the need for
improved patient-tracking systems to reduce loss
to follow-upand tomakepossible further inquiry to
identify barriers to care for patients with EC, such
as stigma, distance to access medical care, or
costs of care. Finally, we acknowledge that al-
though this study included EC cases from a na-
tional referral hospital and the only specialized
cancer treatment center in Tanzania, this sam-
pling probably underrepresents all EC cases in
Tanzania, and it is not possible to derive any
conclusions about incidence rates for the popu-
lation at large.
In conclusion, during 3 consecutive years, a large
number of patients with EC were seen at MNH
and/or ORCI in Dar es Salaam, Tanzania. Patients
traveled long distances to seek care and often
presented with advanced disease. Acknowledging
limitations as a result of the retrospective nature of
this study, these findings will provide initial data to
allow for a review of the diagnostic and therapeutic
strategies applied in this resource-constrained set-
ting. With increased awareness and education
regarding diagnosis and treatments of EC in this
high-incidence area, this knowledge will enable
improved allocation of resources for capacity build-
ing, diagnosis, and treatment. In addition, our
future researchwill evaluate the etiology of the high
incidence of EC in Tanzania, with particular inquiry
into its occurrence among younger adults.
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